Corticotropin releasing factor receptor antagonists
US12005065B2 · kind B2 · utility
0Cited by
8References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2023 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Apr 26, 2043 |
Classification
- Technology area (CPC —)General
Abstract
The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.